Introduction: The Mortality-Incidence Ratio complement [1 -MIR] is an indicator validated in various populations to estimate five-year cancer survival, but its validity remains unreported in Peru. This study aims to determine if the MIR correlates directly with five-year survival in patients diagnosed with the ten most common types of cancer in metropolitan Lima.
Introduction
Cancer is one of the most devastating diseases and is among the leading causes of morbidity and mortality worldwide. The World Health Organization reported that 8.2 million people worldwide died of cancer in 2012 [1] . Cancer is a leading public health problem in Peru and also the second leading cause of death in both sexes [2] . Some cancers are preventable and some are potentially curable. It is thus crucial to study indicators such as survival that help us assess how cancers progress and how health systems respond to them [3, 4] . Studying key indicators allows us to measure their effectiveness and profitability, and helps us plan and manage resources for cancer control [6, 7] .
Accurate population-based cancer registries are needed in order to estimate general cancer survival across populations and survival for specific types of cancer. The lack of active monitoring, even in developed countries with population-based cancer registries, hinders efforts to make reliable five-year survival estimates. Recent studies have therefore assessed the validity of the mortality-incidence ratio complement as an indicator for estimating cancer survival. The MIR complement results from subtracting from the result obtained by dividing the number of deaths by the number of new cases of a specific cancer type recorded during the same time period in a specific population [4, 9, 10] . A higher result of the complement of MIR indicates a better survival rate. A 2010 analysis of seven cancer registries in developing countries examined information on 32 types of cancer, finding that for at least five of the seven countries the complement [1 -MIR] was a good predictor for five-year cancer survival, and largely free of bias [3] . However, the authors also found that the complement overestimated survival in some cancers (oral and liver cancers) and underestimated survival in other cancers (soft tissue, bone, breast, prostate, and oesophagus cancers, as well as myeloma and leukaemia).
To our knowledge, no study has been developed using data from population-based cancer registries in developing countries to estimate the survival. Thus, the validity of the MIR complement as an indicator of survival in these countries remains untested. In Peru, the Metropolitan Lima Cancer Registry (RCLM) is the only registry subject to a quality control system that scrutinises the data that it collects and processes. It has an international certificate and has been an active member of the International Association of Cancer Registries since its creation. This registry was created in 1990, and collects information on all new cancer cases diagnosed in all public and private institutions in Lima and Callao Provinces. The RCLM covers date from 2004 to 2005, when 31,226 new cancer cases were recorded in Lima and Callao [8] . Conducting survival studies using registries such as the RCLM is challenging due to problems related to active monitoring of cancer patients. Survival studies also pose funding and logistical challenges in developing countries such as Peru.
This study aims to assess the validity of the MIR as a predictor of cancer patient survival in metropolitan Lima.
Methodology

Source material
The data used in this study was obtained from RCLM. This information included cancer cases recorded by the National Cancer Institute Cancer deaths included deaths that occurred during the same period and whose cause of death was one of the previously mentioned cancers. Regarding the observed survival data, it was estimated using a study sample of the new cases recorded in the RCLM and the vitality status, of each new case of the sample, was verified five years from the date of diagnosis using data from the RENIEC. RENIEC contains all the data from the national identity document emitted to all Peruvians (born or nationalised) with the unique identity number, names and surnames, date of birth, sex, marital www.ecancer.org 
Sample and sampling
Procedure for calculating survival study sample size Ten cancer types were taken for the study, but it was found that the number of new cases of each one varied significantly; therefore, a representative sample size was calculated for the seven cancer types that exceed 1,000 reported cases (simple random selection without replacement, calculated using the formula K = N/n). Those seven cancer types were breast, stomach, prostate, lung, colon, and cervical cancers and non-Hodgkin's lymphoma. For the cancers with the number of cases reported below 1,000 (liver and thyroid cancer and leukaemia) all cases reported were included. At the same time, subjects who were diagnosed with cancer from death certificates were excluded from the analysis, as including them would impair survival time calculation [11] .
The sample size required was calculated for each cancer type using a simple random sampling without replacement, with the following formula determining required sample size:
where n is the sample size; N is the patient population with each type of cancer; P is the proportion of the population at risk for each type of cancer; Q is the complement of P (Q = 1 -P); E is the estimated error E = 0.035 (3.5%); and Z is 95% confidence (1.96).
Furthermore, sample size was increased 10% to account for the risk of not finding all selected cases (Table 1) .
Procedure for selecting the cases used in the sample
The cases were selected systematically and only for cancers that required calculating the sample size. A sampling frame was created for each type of cancer, which included all the sampling units that form our population, then these units were organised according to reference hospital, numbering them from 1 to N. Our selection interval was determined by using the below formula:
where N is the population size and n is the sample size.
For all cancers, a non-integer value 'K' was obtained, rounded to the nearest whole number by selecting a random number 'a' between 1 and N, adding the K constant to select cases for the sample.
Statistical analysis
Phase 1: MIR calculation
The numbers of deaths and new reported cases were obtained for each type of cancer studied from the RCLM. This allowed us to determine the MIR.
MIR = number of deaths number of new cases
With these data, the complement [1 -MIR] was calculated, expressed as a percentage between 0 and 100. Values approaching 0% represent a poor survival rate and those approaching 100% represent an excellent survival rate.
Phase 2: Observed survival analysis
To determine survival, the Kaplan-Meier method was used. Alive cases were considered when the last check-up occurred at least five years after diagnosis, and deceased cases were considered when RENIEC showed a date of death within five years of diagnosis. The IBM SPSS Statistics 22 program was used to determine the five-year survival probability for each cancer [see Figure 1 
Ethics
The These findings were consistent with what was obtained with the observed survival from the database created using RENIEC data. These results appear in Figure 1 
Discussion
Multiple studies in different countries have used the MIR as an indicator of five-year survival for various types of cancer. Parkin et al confirmed that the MIR is a good indicator of five-year survival when collection of neoplasia incidence and mortality data is rigorous and consistent [10] . To our knowledge, however, no one has studied the MIR as a tool for evaluating survival in Peru. Cancer incidence and mortality vary based on lifestyle, genetics, environment, access to a healthcare system and treatment, and other factors. There was then a need to assess whether MIR is a valid tool for the population of metropolitan Lima. The MIR is a public health tool that makes estimating survival for each type of neoplasia more feasible. Studies of survival allow us to understand patterns and establish the behaviour and burden of each type of neoplasia. The MIR helps us predict future burdens and trends, allowing us to project incidence and mortality for each neoplasia and monitor the disease. These steps are essential to oncology [4, 13] . The MIR also allows us to retrospectively assess populations with shorter or longer five-year survival. This information can then be connected to cancer prevention, diagnosis, and treatment methods in use during the same time period and at the same time determine what actions were taken at the time, and focus on making decisions that will achieve better survival in the future [12, 14] .
The results of our study indicated that the observed survival findings were consistent with the estimate made using the MIR complement. By evaluating and observed survival in the linear regression model, it was found that the ten types of cancer studied fall in a nearly perfect line y = x on the regression line, suggesting a strong correlation. Obtaining a coefficient of determination of R² = 0.9682, it shows that the variations in [1 -MIR] (X) explain 96.82% of the variation in observed survival (Y). It is indicated that the MIR is a valid indicator for five-year survival for the types of cancers studied in the population of metropolitan Lima.
Of the ten cancers studied, nine had a difference of less than 10% between the observed survival and the survival estimated by the 1-MIR. Within these cancers, we must emphasise the thyroid cancer whose observed survival was the same as that estimated by the Although our results confirm the use of MIR to evaluate five-year survival, the limitations of this study must be recognised. First, the MIR can only serve as a valid measure with a population-based cancer registry. Maintaining such registries can be as complicated as actively monitoring cases in order to achieve accurate estimates of survival. In Peru, the only population-based cancer registry is the RCLM, which collects information from all public and private hospitals in the Lima metropolitan area [8] . The efforts of the INEN to maintain the RCLM are complex and require staff, logistics, and a budget. These challenges have prevented INEN from creating cancer registries in other cities and from analysing RCLM data from other years. This lack of resources is a limitation. MIR-based survival calculations require INEN or another institution to continue collecting data and maintain population-based cancer registries over the years. However, this reality is not the same for all countries, other nations like Brazil for example, have achieved greater success in these areas. Brazil has up-to-date registries containing significant data that allows public health agencies to actively monitor patients over time [7] .
Another limitation resulted from gaps in the RENIEC data that made it difficult to confirm survival of selected cases. A portion of cases lacked current information and this could generate a sub-registry of cases from our sample [11] . Therefore, we decided to increase the sample size during the study. Additionally, another point to mention is the simple random sampling used, not stratifying by sex, age, stage of diagnosis, or any other co-variable due to lack of time and funds. However, the aim of our study was to analyse the population of metropolitan Lima as a unit, assessing general survival for each type of neoplasia. Therefore, it should be considered that not stratifying the sample may represent a limitation.
At the same time, another limitation was not calculating MIR for all cancer types, but only for ten specific ones. Ten cancers can be a small number for a linear regression model. Nonetheless, starting with these representative types of cancers is a beginning or starting point to complement them with more areas of studies. Also, it must be emphasised that the studied cancers were selected as most representative in the study population (choosing those with the highest and lowest mortality and the highest incidence, affecting both sexes).
Conclusion
Finally, it can be established that the differences between MIR-estimated survival and observed survival are insignificant. The MIR thus appears to be an appropriate tool for predicting five-year survival for the types of cancer studied in metropolitan Lima. This study then confirms the validity of the MIR only for this population, but provides the basis for new studies and uses of the MIR. Oncologists, epidemiologists, public health researchers, and healthcare managers can use the MIR to study the population of metropolitan Lima [13, 15] .
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